Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

Autor: Valentín García-Gutiérrez, Nuria Hernán, José María Guinea, Luis Felipe Casado-Montero, Gloria González, Fernando Ortega Rivas, Ana Sebrango, Angel Ramirez Payer, Miguel Piris-Villaespesa, Juan Luis Steegmann, M.A. Fernandez, Juan Carlos Hernández-Boluda, Esperanza Romero, Dragana Milojkovic, Guillermo Ortí, Sandra Valencia, Guiomar Bautista Carrascosa, Beatriz Cuevas Ruiz, Jose Manuel Puerta, Isabel Mata Vázquez, A García, Elena Amustio Díez, María-José Ramírez, Ana Iglesias Pérez, Alejandra Martínez-Trillos, Josep Maria Martí Martí-Tutusaus, José Tallón, Simone Claudiani, Concepción Boqué, Pilar Giraldo, Natalia De Las Heras Rodríguez, Angeles Portero, Maria Luisa Martin Mateos, Ana Rosell, Antonio Jiménez-Velasco, Rolando Vallansot, Jose Luis Lopez Lorenzo, Maria del Carmen García Garay, Alicia Senín, Andres Romo, Silvanna Saavedra Saavedra

Publikováno v: ANNALS OF HEMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Bosutinib is a second-generation tyrosine kinase inhibitor (2GTKI) approved at 400 mg once daily (QD) as first-line therapy in patients with chronic myeloid leukemia (CML) patients and at 500 mg QD in patients who are resistant to or intolerant of pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::409aa97929066edc3abfd01bfbc0a2e8
https://pubmed.ncbi.nlm.nih.gov/30446802

Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

Autor: Valentín, García-Gutiérrez, Alejandra, Martinez-Trillos, Jose Luis, Lopez Lorenzo, Guiomar, Bautista, Maria Luisa, Martin Mateos, Alberto, Alvarez-Larrán, Ana, Iglesias Pérez, Andrés, Romo Collado, Angeles, Fernandez, Angeles, Portero, Beatriz, Cuevas, Concepción, Ruiz, Esperanza, Romero, Fernando, Ortega, Isabel, Mata, José, Tallón, Maria Del Carmen, García Garay, María José, Ramirez Sánchez, Natalia, de Las Heras, Pilar, Giraldo, Sabela, Bobillo, José María, Guinea, Guillermo, Deben, Sandra, Valencia, Ana, Sebrango, Concepción, Boqué, Begoña, Maestro, Juan Luis, Steegmann

Publikováno v: American journal of hematology. 90(5)

The role of bosutinib as rescue treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine kinase inhibitors (TKIs) is currently unknown. We report here the largest series (to our knowl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b6cf05ee1b2903a22595edfe37a5f9ca
https://pubmed.ncbi.nlm.nih.gov/25683327

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Autor: Maria del Carmen García Garay, Concepción Ruiz, Alejandra Martinez-Trillo, Andrés Romo Collado, Ana Iglesias Pérez, María José Sánchez, Isabel Mata, Jose Luis Lopez Lorenzo, Guiomar Bautista, Juan Luis Steegmann, Beatriz Cuevas, Ana Sebrango, Alberto Alvarez, Guillermo Deben, Fernando Ortega, Esperanza Romero, Concepción Boqué, Maria Luisa Martin Mateos, Sandra Valencia, Angeles Fernandez, Angeles Portero, Pilar Giraldo, Sabela Bobillo, Natalia de las Heras, José Tallón, José María Guinea, Valentín García-Gutiérrez, Begoña Maestro

Publikováno v: Blood. 124:5523-5523

Second-generation TKIs have demonstrated efficacy and an acceptable tolerability in patients (pts) with chronic myeloid leukemia (CML); however, new data from so called “off target” side effects have been published. For example, serious concerns

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51e4792cc83943dc85b8376385f37196
https://doi.org/10.1182/blood.v124.21.5523.5523

La empresa informativa: Notas metodológicas para la construcción del concepto.

Autor: José Tallón

Publikováno v: Documentación de las Ciencias de la Información, Vol 5 (1981)

Sin resumen

Externí odkaz: https://doaj.org/article/f93a383b30b24de2b8480a45096aaac8